Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Al-Batran, Salah-Eddin, Prof, Hofheinz, Ralf D, Prof, Pauligk, Claudia, PhD, Kopp, Hans-Georg, MD, Haag, Georg Martin, MD, Luley, Kim Barbara, MD, Meiler, Johannes, MD, Homann, Nils, Prof, Lorenzen, Sylvie, MD, Schmalenberg, Harald, MD, Probst, Stephan, MD, Koenigsmann, Michael, Prof, Egger, Matthias, MD, Prasnikar, Nicole, MD, Caca, Karel, Prof, Trojan, Jörg, Prof, Martens, Uwe M, Prof, Block, Andreas, MD, Fischbach, Wolfgang, Prof, Mahlberg, Rolf, MD, Clemens, Michael, Prof, Illerhaus, Gerald, Prof, Zirlik, Katja, MD, Behringer, Dirk M, Prof, Schmiegel, Wolff, Prof, Pohl, Michael, MD, Heike, Michael, Prof, Ronellenfitsch, Ulrich, MD, Schuler, Martin, Prof, Bechstein, Wolf O, Prof, Königsrainer, Alfred, Prof, Gaiser, Timo, Prof, Schirmacher, Peter, Prof, Hozaeel, Wael, MD, Reichart, Alexander, MD, Goetze, Thorsten O, MD, Sievert, Mark, MD, Jäger, Elke, Prof, Mönig, Stefan, Prof, Tannapfel, Andrea, Prof
Published in The lancet oncology (01.12.2016)
Published in The lancet oncology (01.12.2016)
Get full text
Journal Article